Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
GlobeNewswire
· Newly outlined pathway provides a practical, expedient, repeatable immunobridging approach to potential emergency use..
